The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Clinical Implications of Basic Research
PreviousPrevious
Volume 359:967-969 August 28, 2008 Number 9
NextNext

Targeting Intraocular Neovascularization and Edema — One Drop at a Time
Lloyd Paul Aiello, M.D., Ph.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
Barring death, blindness is one of the most feared complications of human disease. In developed countries worldwide, the vast majority of visual loss results from pathologic neovascularization of the choroid and retina or retinal edema, conditions that are thought to be mediated primarily by the angiogenic and vasopermeability molecule called vascular endothelial growth factor (VEGF). These complications are treated with either laser photocoagulation, which destroys areas of otherwise functional retina, or antiangiogenic agents that are repeatedly injected into the center of the eye. Recent studies by Scheppke et al.1 and Doukas et al.2 indicate that a different approach may be . . . [Full Text of this Article]


Source Information

From the Beetham Eye Institute and Section of Eye Research, Joslin Diabetes Center, and the Department of Ophthalmology, Harvard Medical School — both in Boston.



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.